Pancreatic Cancer Research

ResearcherIRCCS Ospedale San RaffaeleActive in the last 2 years

Paolo Passoni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1975-9768; OpenAlex author ID A5014631551. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2012: 3 papers · 2013: 2 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 16

  1. A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.09.026↗
  2. Temporal Validation of an FDG-PET-Radiomic Model for Distant-Relapse-Free-Survival After Radio-Chemotherapy for Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers17061036↗
  3. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ctro.2024.100778↗
  4. Stomach and duodenum dose-volume constraints for locally advanced pancreatic cancer patients treated in 15 fractions in combination with chemotherapy. First author DOI 10.3389/fonc.2022.983984↗
  5. Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Co-author DOI 10.1007/s00280-020-04190-1↗
  6. Training and validation of a robust PET radiomic-based index to predict distant-relapse-free-survival after radio-chemotherapy for locally advanced pancreatic … First author DOI 10.1016/j.radonc.2020.07.003↗
  7. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. Co-author DOI 10.1186/s12885-019-5790-2↗
  8. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreati… Co-author DOI 10.1016/j.ejca.2018.07.007↗
  9. Quantifying the robustness of [18F]FDG-PET/CT radiomic features with respect to tumor delineation in head and neck and pancreatic cancer patients. Co-author DOI 10.1016/j.ejmp.2018.05.013↗
  10. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdx495↗
  11. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic… Co-author DOI 10.1038/bjc.2016.209↗
  12. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a pha… Co-author DOI 10.1016/j.ijrobp.2013.09.012↗
  13. Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced panc… First author DOI 10.1016/j.radonc.2013.05.011↗
  14. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirub… Co-author DOI 10.1007/s00280-011-1680-2↗
  15. Role of PET/CT in the clinical management of locally advanced pancreatic cancer. Co-author DOI 10.1177/030089161209800516↗
  16. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Co-author DOI 10.1245/s10434-011-2205-2↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michele Reni · 14 shared papers, 2012–2026 · strength 1.33
  2. Nadia Gisella Di Muzio · 10 shared papers, 2012–2026 · strength 1.05
  3. Claudio Fiorino · 6 shared papers, 2018–2026 · strength 0.93
  4. Maria Picchio · 5 shared papers, 2012–2026 · strength 0.63
  5. Marina Macchini · 4 shared papers, 2018–2026 · strength 0.58
  6. Martina Mori · 4 shared papers, 2018–2025 · strength 0.52
  7. Giulia Orsi · 3 shared papers, 2021–2026 · strength 0.52
  8. Sara Broggi · 4 shared papers, 2018–2024 · strength 0.49
  9. Gianpaolo Balzano · 7 shared papers, 2012–2024 · strength 0.44
  10. M. De Vincenzi · 2 shared papers, 2025–2026 · strength 0.43
  11. Massimo Falconi · 5 shared papers, 2016–2024 · strength 0.43
  12. Umberto Peretti · 3 shared papers, 2018–2024 · strength 0.36
  13. Claudio Doglioni · 5 shared papers, 2012–2021 · strength 0.32
  14. Giulio Belfiori · 2 shared papers, 2021–2024 · strength 0.29
  15. Domenico Tamburrino · 2 shared papers, 2021–2024 · strength 0.29
  16. Stefano Cascinu · 2 shared papers, 2021–2024 · strength 0.29
  17. Silvia Matilde Zanon · 4 shared papers, 2016–2021 · strength 0.29
  18. Giovanni Mauro Cattaneo · 4 shared papers, 2013–2022 · strength 0.28
  19. Martina Mori · 1 shared paper, 2026 · strength 0.22
  20. Catia Carconi · 1 shared paper, 2026 · strength 0.22
  21. Luca Gianni · 3 shared papers, 2016–2018 · strength 0.18
  22. Paolo Giorgio Arcidiacono · 3 shared papers, 2016–2018 · strength 0.18
  23. R. Calandrino · 3 shared papers, 2013–2018 · strength 0.14
  24. Marta Chiaravalli · 2 shared papers, 2017–2018 · strength 0.12
  25. Stefano Cereda · 4 shared papers, 2012–2013 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.